ClinicalTrials.gg
RecruitingNCT03059069Updated Feb 24, 2025

The Effect of Gliatamin (Chonline Alphoscerate) on Depressive Mood in Type 2 Diabetes Patients

A Phase 4 interventional study of Chonline Alphoscerate and Placebo Oral Tablet in Type2 Diabetes With Depressive Mood, sponsored by Yonsei University. Recruiting at 1 site in Korea, Republic of. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2025-02-24.

Sponsored by Yonsei University · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 4 months ago, but the record still lists the study as recruiting.
  • Registered 8 months after the study started (first participant enrolled Jun 2016, registered Feb 2017).
  • Started Jun 2016; still recruiting 10 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Diabetes Mellitus, Type 2 by Yonsei University — 5 open to participants now, 6 under way, none of them phase 3. Diabetes Mellitus, Type 2 · Yonsei University.

Planned enrollment
8th of 13
60 · median 61
Started
2016
with 3 others
Phase 4
10 of 20
3 open now
Registered
11th of 20
by date

Among the 20 studies in Diabetes Mellitus, Type 2 by Yonsei University, this one is the 8th largest by planned enrollment of the 13 interventional ones that give a count, is one of 4 that started in 2016, is one of 10 in phase 4, and was the 11th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

5 of the 20 studies in Diabetes Mellitus, Type 2 by Yonsei University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Diabetes Mellitus, Type 2 by Yonsei University, or all of them as a file.
02

Study summary

The aim of this study is to investigate the effect of Gliatamin (chonline alphoscerate) on depressive mood in type 2 diabetes patients and demonstrate the impact of improved depressive mood could be influence the patient's quality of life and glycemic control.

Read the detailed description

The prevalence of depressive disorder is higher in individuals with chronic diseases, and the screening and management of depression is emphasized. Diabetes mellitus (DM) is a class of chronic disease and the incidence of DM has been increasing. According to previous study, 31.1% of patients with DM accompanied with depressive disorders which was higher than that of subjects without DM. Furthermore, DM as well as depression is known for risk factor for dementia.

The choline metabolism involves in neuropathology of depressive disorders and individuals with depressive disorders showed the lower level of choline concentration. Choline alphoscerate is cholinergic precursor and showed the favorable clinical results in dementia management.

As pseudodementia can be presented as depressive disorder and choline alphoscerate would be an option for these cases. Therefore, the aim of this study is to investigate the effect of Gliatamin (chonline alphoscerate) on depressive mood in type 2 diabetes patients and demonstrate the impact of improved depressive mood could be influence the patient's quality of life and glycemic control.

03

Conditions studied

  • Type2 Diabetes With Depressive Mood
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 2 diabetic patients
  • Age ≥ 50
  • Glycemic control: ≤ 10.0%
  • 10 ≤ Beck Depression Inventory (BDI) \<30 points
  • Participants who can undergo in case of being in childbearing period
  • Understands the study procedure, alternatives, and risks and voluntarily agrees to participate by giving written informed concent

Exclusion criteria

Exclusion Criteria:

  • Type 1 diabetes, Secondary diabetes, gestational diabetes
  • Ongoing dementia treatment or anti-depressive disorder medication
  • Uncontrolled psychiatric disorder
  • BDI ≥ 30 points
  • Heavy alcoholics
  • Underlying chronic liver disease (hemochromatosis, liver cell carcinoma, liver disease, liver cirrhosis, chronic viral hepatitis)
  • Allergy or to target medication or any of its components
  • Renal failure, moderate or severe renal impairment (estimated \< 30 mL/min/1.73 m2), or ongoing dialysis
  • Abnormal liver function (/ALT > x3 upper normal limit)
  • History of alcohol or drug abuse in the previous 3 months
  • Premenopausal women who are nursing or pregnant
  • (HIV) or human immunodeficiency virus (AIDS)
  • chronic pancreatitis or pancreatic cancer
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Glitamin

    800mg/day

    Drug: Chonline Alphoscerate

  • Placebo comparator
    Placebo

    same shape, color, size tablet as Glitamin

    Drug: Placebo Oral Tablet

Interventions

  • DrugChonline Alphoscerate

    Patients treated with Chonline Alphoscerate as add on therapy to their medication

    Also known as: Gliatamin

  • DrugPlacebo Oral Tablet

    Patients maintain their medication with either Gliatamin or placebo for 6 months.

06

What researchers measure

Primary outcomes

  1. changes in Hamilton Depression Rating Scale (HDRS)

    The HDRS will be scored by face-to-face interview.

    Time frame: 6 months after the treatment

Secondary outcomes

  1. changes in Mini-mental state examination (MMSE) score

    MMSE questionnaire will be checked by careful interview and self-reported.

    Time frame: 6 months after the treatment

  2. glucometabolic parameters

    fasting glucose (mg/dL)

    Time frame: 6 months after the treatment

  3. glucometabolic parameters

    postprandial 2h glucose (mg/dL)

    Time frame: 6 months after the treatment

  4. glucometabolic parameters

    fasting insulin (uIU/mL)

    Time frame: 6 months after the treatment

  5. glucometabolic parameters

    homeostasis model assessment for insulin resistance (mg/dL•uIU/mL)

    Time frame: 6 months after the treatment

  6. glucometabolic parameters

    aspartate aminotransferase (IU/L)

    Time frame: 6 months after the treatment

  7. glucometabolic parameters

    alanine aminotransferase (IU/L)

    Time frame: 6 months after the treatment

  8. glucometabolic parameters

    glycated hemoglobin (%)

    Time frame: 6 months after the treatment

  9. glucometabolic parameters

    glycoalbumin (%)

    Time frame: 6 months after the treatment

  10. glucometabolic parameters

    triglyceride (mg/dL)

    Time frame: 6 months after the treatment

  11. glucometabolic parameters

    low-density lipoprotein (mg/dL)

    Time frame: 6 months after the treatment

  12. glucometabolic parameters

    high-density lipoprotein (mg/dL)

    Time frame: 6 months after the treatment

07

Study locations

1 of 1 sites recruiting
  • Yonsei University College of Medicine, Department of Internal Medicine, Division of Endocrinology, Severance Hospital, Diabetes Center
    Seoul, 03722, Korea, Republic of
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2016 (actual). Primary completion is estimated for Jun 2025, 108 months after the start.

Of 320 non-industry phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 49. This study's planned 108 months is above that.

Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 15, 2017
First posted
Feb 23, 2017
StartActual
Jun 1, 2016
Primary completionEst.
Jun 30, 2025
CompletionEst.
Jun 30, 2025
Last update
Feb 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03059069
Lead sponsor
Yonsei University
Responsible party
Sponsor
First posted
Feb 23, 2017
Start date
Jun 1, 2016
Primary completion
Jun 30, 2025 (estimated)
Completion
Jun 30, 2025 (estimated)
Last update
Feb 24, 2025

Study contacts

Bong-Soo Cha, MD, Ph.D
Contact
bscha@yuhs.ac
82-2-2228-5457

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion